/PRNewswire/ NephroSant™ a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys, with a.
/PRNewswire/ NephroSant, Inc. a biotechnology company dedicated to accelerating the diagnosis of early kidney damage in native and transplanted kidneys,.
NephroSant Announces $16 Million Series A, Led by DaVita Venture Group
SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2021 / NephroSant, a kidney health spin out of UC San Francisco, today announced it has closed its oversubscribed Series A funding round of $16 million. DaVita Venture Group led the investment round, with participation from DigitalDx Ventures and other previous investors. The funding will be used to support research and development and the launch of NephroSant s first product: Qsant, a needle-free urine test that helps determine if a patient s body is rejecting a transplanted kidney. We are very excited about the opportunity to work with DaVita, a recognized leader in kidney care, said Dr. Minnie Sarwal, CEO and founder of NephroSant, as well as Professor of Surgery at UCSF. Their expertise and experience provide the perfect complement to the vision and focus of NephroSant to redefine kidney health.